A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Condition:   SmallpoxInterventions:   Biological: IMVAMUNE;   Biological: IMVAMUNESponsor:   Bavarian NordicCompleted - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials